FDA gives OK to Mesoblast for mesenchymal precursor cell production

11/20/2012 | Australian Life Scientist

Mesoblast and the FDA have reached an agreement regarding the production process for mesenchymal precursor cells to be used in late-stage clinical trials for the treatment of congestive heart failure and other conditions. The FDA and Mesoblast put in place a path for the possible commercial production of the company's cell therapy products.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC